Navigation Links
AMICAS Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007
Date:2/28/2008

k, at cost, 6,824,192 and

6,523,392 shares (22,443) (21,640)

Total stockholders' equity 108,246 107,555

Total Liabilities and Stockholders' Equity $128,441 $126,871

Condensed Consolidated Statements Of Operations

(in thousands, except per share data)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

Revenues

Maintenance and services $9,645 $8,991 $38,175 $36,258

Software licenses and system sales 2,007 2,453 11,713 13,179

Total revenues 11,652 11,444 49,888 49,437

Costs and expenses

Cost of revenues:

Maintenance and services (a) 4,134 3,898 16,469 15,003

Software licenses and system sales,

including amortization of software

costs of $489, $489, $1,957 and

$1,958, respectively 1,326 1,424 6,486 7,644

Selling, general and administrative (b) 5,662 5,866 21,809 21,770

Research and development (c) 2,115 2,075 8,527 8,705

Depreciation and amortization 284 294 1,120 1,238

13,521 13,557 54,411 54,360

Operating loss (1,869) (2,113) (4,523) (4,923)

Interest income 991 988 3,870 3,753

Loss from continuing operations,

before income taxes (878) (1,125) (653) (1,170)

Provision for income taxes 24 21 209 84

Loss from continuing operations (902) (1,146) (862) (1,254)

Gain on sale
'/>"/>

SOURCE AMICAS, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. AMICAS Schedules Fourth Quarter and 2007 Year End Earnings Results Conference Call
2. AMICAS to Present at UBS Global Healthcare Services Conference
3. MedQuest Standardizes on AMICAS Vision Series PACS
4. AMICAS Solutions Closing the Loop in Radiology Communications
5. AMICAS Transforms Critical Results Notification with RadStream
6. AMICAS Launches Vision Reach 2.0, a Tool to Help Radiology Businesses Grow
7. Webcast Alert: AMICAS, Inc. Announces 3rd Quarter 2007 Earnings Conference Call
8. Radiology Ltd. Chooses AMICAS as End-to-End Solutions Provider
9. AMICAS Schedules Third Quarter Earnings Call
10. AMICAS to Present at William Blair & Company Small Cap Growth Stock Conference
11. AMICAS Hosts Complimentary DRA Education Session Featuring Timothy Trysla
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2008)...an farm, FDA announces , , FRIDAY, July...ering the first big clue in the nationwide salmone...ay that tainted jalapeno peppers had been definiti...d and Drug Administration gave the all-clear to ja...tes, but warned consumers to avoid any raw jalapen...
(Date:7/25/2008)...ter & Olsen LLP has filed a,class action lawsuit a...,"Company") (Nasdaq: ARTC ) and certain of its of...District of Texas on behalf of all persons or,enti...m January 24, 2008,through July 18, 2008 (the "Com... or entities who purchased call options or sold pu...
(Date:7/25/2008)...inancial results -, LAVAL, QC, July 25 /PRNewswir...DSS) today announced that it will host a conferenc...scuss its second quarter 2008,financial results. L...cial,results via news release at approximately 7:0...ll by telephone, dial 416-646-3095 or,1-800-814-48...
(Date:7/25/2008)...FirstCall/ -- Thoratec,Corporation (Nasdaq: THOR ...atory support therapies to save, support and resto...port its operating results for the second,quarter ...uly 31., The company will hold a conference call ...ivities to all interested parties at 1:30 p.m.,Pa...
Breaking Medicine News(10 mins):Health News:Mexican Peppers ID'd as Salmonella Culprits 2Health News:Mexican Peppers ID'd as Salmonella Culprits 3Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2
...tics show that drug deaths in Scotland have droppe...rom drugs in Scotland in 2005 compared with 356 in...is a tragedy and reminds us that drug abuse is a b...es and communities across Scotland," said Deputy J...
...l of growing by a whopping 25 percent annually to ...by 2012, Tourism Minister Ambika Soni said Wednesd... at the response from foreign patients, we estimat...llion annually by 2012," said Soni while releasing...
... brain injury, the simplest movements like putting...to open a door can be daunting for patients.// Com...lternative to traditional physical rehabilitation ...lled with an antispasmodic drug that is implanted ...
...ied after getting an overdose of chemotherapy drug...ly, yesterday.// Dr. Tony Fields told a news conf...s a most unfortunate incident. She died from inter...e.” "This is one of our worst nightmares," said Fi...
Other Medicine News:Health News:Medical Tourism can Fetch Rs.100 bn Annually by 2012 2Health News:Medical Tourism can Fetch Rs.100 bn Annually by 2012 3Health News:Computer Assisted Neuro-Rehabilitation Devices Way of the Future 2Health News:Overdose of Chemotherapy Drug kills a woman 2
(Date:7/23/2008)...Newswire-FirstCall/ -- Dendreon Corporation,(Nasda...ependent Data,Monitoring Committee (IDMC) to revie...survival relating to the Company,s Phase 3 IMPACT ...nt, also known as D9902B) clinical trial,of PROVEN...vestigational,active cellular immunotherapy for th...
(Date:7/22/2008)...sults from a multi-center 293-patient European, t... Exchange Symbol: CYT, MONTREAL, July 22 /PRNewsw...e global leader in cryotherapy products to treat c...reviously presented from three,European study cent...(R),were published earlier today in the Journal o...
(Date:7/22/2008)...scuss Development Plan Completed Successfully, DU...marin Corporation,plc (NASDAQ: AMRN ) today annou...at the U.S. Food and Drug Administration (FDA) to ...the treatment of,hypertriglyceridemia. Following t...se 3 with AMR101 in hypertriglyceridemia., Dr. De...
(Date:7/22/2008)...g Lantus(R) and Apidra(R) Resulted in Significant,...s, Whatever the Algorithm ...wire/ -- Results from the "Adjust to,Target in Typ...Carbohydrate,Counting for Adjustment of Mealtime I...rican Diabetes Association,s (ADA) medical journal...
Breaking Medicine Technology:Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4ViroPharma to Present at Two Upcoming Healthcare Conferences 1898 1ViroPharma to Present at Two Upcoming Healthcare Conferences 1898 2Story ideas from the Journal of Biological Chemistry 1304 1Story ideas from the Journal of Biological Chemistry 1304 2Serum carcinoembryonic antigen level can reflect adrenal adenoma 6784 1Serum carcinoembryonic antigen level can reflect adrenal adenoma 6784 2Proposal to step up cardiovascular disease research 1299 1Proposal to step up cardiovascular disease research 1299 2
...asound Demonstrates Utility in Evaluating Drug,Eff...ntial for HDL,Therapy , ,PLEASANTON, CA, Mar 30, 2... Sciences, Inc. (NASDAQ: LIPD) Dr. H. Bryan Brewer..., Inc., concluded from,the wide range of presentat...(ACC) Meeting in New Orleans that the rationale fo...
...e Astellas Commitment to Overcoming Critical,Short... April 02, 2007 /PRNewswire/ --Study results,prese...robiology,and Infectious Diseases (ECCMID) show th...icafungin, both have the potential,to meet a signi...pital-acquired infections (HAIs). , Hospital-acqui...
Other Medicine Technology:Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 2Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 3Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 4Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 5Data on Telavancin and Micafungin Hold Promise of New Therapeutic,Options in Fight Against Serious Infectious Disease 2Data on Telavancin and Micafungin Hold Promise of New Therapeutic,Options in Fight Against Serious Infectious Disease 3Data on Telavancin and Micafungin Hold Promise of New Therapeutic,Options in Fight Against Serious Infectious Disease 4Data on Telavancin and Micafungin Hold Promise of New Therapeutic,Options in Fight Against Serious Infectious Disease 5
Delicate curved shafts with light crisscross serrations. Serrated handle with polished finish. Most popular size or model.
Delicate cross serrated lightly curved tips with serrated handle and polished finish. Most popular size or model.
Delicate lightly curved tips, 1 x 2 mouse style teeth. Serrated handle with polished finish.
Straight tubular shaft with delicate 1.5 mm oval jaws. Squeeze barrel style handle with tip guard and polished finish.
Medicine Products: